Immutep Quarterly Activities Report Q4 FY24
Provided By GlobeNewswire
Last update: Jul 31, 2024
Media Release
SYDNEY, AUSTRALIA, July 31, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, provides an update on its activities for the quarter ended 30 June 2024 (Q4 FY24).
Read more at globenewswire.com
